Evidence map›Paper›PMID 35047458›Full record

ArticleJournal of cancer prevention2021

Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.

Altaf Mohammed, Roderick H Dashwood, Sally Dickinson, Mary L Disis, Elizabeth M Jaffee, Bryon D Johnson, Samir N Khleif, Michael N Pollak, Jeffrey Schlom, Robert H Shoemaker and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer prevention, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Altaf MohammedChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.ORCID https://orcid.org/0000-0003-1058-6909
Roderick H DashwoodCenter for Epigenetics & Disease Prevention, Texas A&M Health, College of Medicine, Houston, TX, USA.ORCID https://orcid.org/0000-0003-0351-4034
Sally DickinsonUA Cancer Center, University of Arizona, Tucson, AZ, USA.ORCID https://orcid.org/0000-0002-2049-543X
Mary L DisisUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0001-7653-4648
Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-3841-6549
Bryon D JohnsonDepartment of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0001-7416-3396
Samir N KhleifThe Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.ORCID https://orcid.org/0000-0003-2707-5224
Michael N PollakLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0003-3047-0604
Jeffrey SchlomLaboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD, USA.ORCID https://orcid.org/0000-0001-7932-4072
Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.ORCID https://orcid.org/0000-0003-3608-1714
Sasha E StantonEarle A. Chiles Research Institute, Portland, OR, USA.ORCID https://orcid.org/0000-0002-4300-551X
Georg T WondrakDepartment of Pharmacology and Toxicology, College of Pharmacy and UA Cancer Center, University of Arizona, Tucson, AZ, USA.ORCID https://orcid.org/0000-0003-4799-8608
Ming YouCenter for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.ORCID https://orcid.org/0000-0002-9741-268X
Hao ZhuUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID https://orcid.org/0000-0002-8417-9698
Mark Steven MillerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.ORCID https://orcid.org/0000-0003-1191-0977

Funding

Targeted Prevention for Non-Melanoma Skin CancerP01CA229112 · NCI · UNIVERSITY OF ARIZONA · PI MANSOUR, HEIDI M. · 2019 to 2023
$7.1M
RNA Expression Profiling after TLR4 Inhibition in UV-induced Mouse Skin TumorsR03CA230830 · NCI · UNIVERSITY OF ARIZONA · PI DICKINSON, SALLY E · 2018 to 2019
$154k
NCI NIH HHS L30 CA187639NCI NIH HHS P01 CA229112NCI NIH HHS R03 CA230830
6 · The paper itself

Abstract

The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the "Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents" as a virtual 2-day workshop on September 13 to 14, 2021. The main goals of this workshop were to foster the exchange of ideas and potentially new collaborative interactions among leading cancer immunoprevention researchers from basic and clinical research and highlight new and emerging trends in immunoprevention. The workshop included an overview of the mechanistic classes of immunomodulatory agents and three sessions covering the gamut from preclinical to clinical studies. The workshop convened individuals working in immunology and cancer prevention to discuss trends in discovery and development of immunomodulatory agents individually and in combination with other chemopreventive agents or vaccines.

Indexed as

ChemopreventionClinical trialsImmunomodulatory agentsImmunopreventionPreventive vaccines

Identifiers

PMID35047458
PMCPMC8749317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.